The monitoring of DEA-controlled substances for suspicious orders is well-known. Companies have an obligation to not only implement a system to identify orders of unusual size, frequency, and pattern for DEA-controlled substances, but also to take similar measures for monitoring other product categories (State Controlled, High Potential for Diversion, Rx). This includes a establishing a means of evaluating and reviewing order data that may warrant further investigation. Our webinar will cover the monitoring of other types of orders, such as orders for products that are designated as a controlled substance at the state level, products that have a high potential for diversion, and Rx products.
Data, AI, and expertise empower Commercial Solutions to optimize strategy, accelerate market access, and maximize brand performance.
Navigate the challenge of compliance, and its vital association with quality
.svg){kind=icon}
